Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2013 October;104(5) > Minerva Medica 2013 October;104(5):545-61

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

REVIEWS   

Minerva Medica 2013 October;104(5):545-61

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Medical treatment of hepatocellular carcinoma

Germano D., Tinessa V., Barletta E., Cannella L., Daniele B.

Oncology Unit, “G. Rummo Hospital”, Benevento, Italy


PDF


The management of hepatocellular carcinoma (HCC) has substantially changed in the past few decades, the introduction of novel therapies (such as sorafenib) have improved patient survival. Nevertheless, HCC remains the third most common cause of cancer-related deaths worldwide. Decision-making largely relies on evidence-based criteria, as showed in the US and European clinical practice guidelines, which endorse five therapeutic recommendations: resection; transplantation; radiofrequency ablation; chemoembolization; and sorafenib. However, areas still exist in which uncertainty precludes a strong recommendation, such as the role of adjuvant therapies after resection, radioembolization with yttrium-90 or second-line therapies for advanced HCC. Many clinical trials that are currently ongoing aim to answer these questions. The first reported studies, however, failed to identify novel therapeutic alternatives (that is, sunitinib, erlotinib or brivanib). Efforts that focus on the implementation of personalized medicine approaches in HCC will probably dominate research in the next decade.

top of page